Abstract 96P
Background
To compare the doublet gemcitabine and cisplatin which is a standard of care in locally advanced or metastatic gall bladder cancer to a triplet gemcitabine, cisplatin and nab paclitaxel regime which has shown promising results in a single arm phase II study.
Methods
A total of 60 patients with locally advanced or metastatic gall bladder cancer were randomized 30 in each arm after imaging [contrast enhanced CT scan of chest, abdomen, and pelvis / MRI abdomen and pelvis with CECT chest /whole-body PET CT scan] and biopsy. Arm A received two drugs gemcitabine 1000mg/m2 i.v and cisplatin 25mg/m2 i.v on Day1 and Day8 of 21-day cycle and arm B received three drugs gemcitabine, 1000 mg/m2 , cisplatin, 25 mg/m2 , and nab-paclitaxel, 125 mg/m2 , on days 1 and 8 of 21-day cycle. Evaluation was done post 3 and 6 cycles of chemotherapy. Then patients were followed up every 6 months for 2 years period for assessment of primary and secondary endpoints of the study.
Results
The combination of gemcitabine and cisplatin (arm A) showed an overall radiological response rate (complete response and partial response) of 13.3% while it was 61.9 % in patients who received gemcitabine, cisplatin, and nab-paclitaxel. This difference was statistically significant with a p-value of 0.004. The median progression-free survival for the patients who received gemcitabine and cisplatin was 4.5 months (95% CI, 4.0-4.9) vs 7.6 months (95% CI, 3.9-11.2) for the patients who were treated with gemcitabine, cisplatin, and nab-paclitaxel. This difference was statistically significant with a p-value of ≤ 0.05. The median overall survival for the doublet was 9.2 months (95% CI 2.6-15.7) vs not reached for the patients who were treated with gemcitabine, cisplatin, and nab-paclitaxel. There was no increase in grade 3 adverse events with the addition of nab-paclitaxel.
Conclusions
To conclude, our study showed that the triplet chemotherapy with gemcitabine and cisplatin and nab-paclitaxel was significantly better in terms of overall response rate, and median progression-free survival with a longer follow up needed to comment on median overall survival.
Clinical trial identification
CTRI/2021/09/036362.
Editorial acknowledgement
Legal entity responsible for the study
C. Khatri.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17